CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Antibe Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Antibe Therapeutics Inc
15 Prince Arthur Avenue
Phone: (905) 726-0995p:905 726-0995 Toronto, ON  M5R 1B2  Canada Ticker: ATEATE

Business Summary
Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20193/31/2019Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Walter M.Macnee 8/30/2013 2/26/2013
President, Chief Executive Officer, Secretary, Director DanielLegault 56 8/30/2013 5/5/2009
Founder, Chief Scientific Officer, Director John L.Wallace 57 8/30/2013 5/5/2009
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Citagenix Inc. 1111 Chomedey A-13 East Laval QC Canada

Business Names
Business Name
4B7
ATE
Citagenix Inc.

General Information
Number of Employees: 3 (As of 3/31/2013)
Outstanding Shares: 279,780,749 (As of 11/7/2019)
Stock Exchange: CVE
Fax Number: (905) 570-5103


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 12, 2019